TY  - JOUR

T1  - 2020TiP SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations

JO  - Annals of Oncology

UR  - http://dx.doi.org/10.1016/j.annonc.2024.08.2106

PY  - 2024/09/01

AU  - Loriot Y

AU  - Necchi A

AU  - Hussain SA

AU  - De Velasco Oria GA

ED  - 

DO  - DOI: 10.1016/j.annonc.2024.08.2106

PB  - Elsevier BV

VL  - 35

SP  - S1163

EP  - S1164

Y2  - 2024/12/22

ER  -